Tau positron emission tomographic imaging in aging and early Alzheimer disease

Keith A. Johnson, Aaron Schultz, Rebecca A. Betensky, J. Alex Becker, Jorge Sepulcre, Dorene Rentz, Elizabeth Mormino, Jasmeer Chhatwal, Rebecca Amariglio, Kate Papp, Gad Marshall, Mark Albers, Samantha Mauro, Lesley Pepin, Jonathan Alverio, Kelly Judge, Marlie Philiossaint, Timothy Shoup, Daniel Yokell, Bradford DickersonTeresa Gomez-Isla, Bradley Hyman, Neil Vasdev, Reisa Sperling

Research output: Contribution to journalArticlepeer-review


Objective Detection of focal brain tau deposition during life could greatly facilitate accurate diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and development of disease-modifying therapies. Methods We acquired tau positron emission tomography (PET) using 18F T807 (AV1451), and amyloid-β PET using 11C Pittsburgh compound B (PiB) in older clinically normal individuals, and symptomatic patients with mild cognitive impairment or mild AD dementia. Results We found abnormally high cortical 18F T807 binding in patients with mild cognitive impairment and AD dementia compared to clinically normal controls. Consistent with the neuropathology literature, the presence of elevated neocortical 18F T807 binding particularly in the inferior temporal gyrus was associated with clinical impairment. The association of cognitive impairment was stronger with inferior temporal 18F T807 than with mean cortical 11C PIB. Regional 18F T807 was correlated with mean cortical 11C PiB among both impaired and control subjects. Interpretation These findings suggest that 18F T807 PET could have value as a biomarker that reflects both the progression of AD tauopathy and the emergence of clinical impairment.

Original languageEnglish (US)
Pages (from-to)110-119
Number of pages10
JournalAnnals of Neurology
Issue number1
StatePublished - Jan 1 2016

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Tau positron emission tomographic imaging in aging and early Alzheimer disease'. Together they form a unique fingerprint.

Cite this